Abstract
Endocrine-disrupting chemicals (EDCs) are a heterogeneous group of natural and man-made chemicals from environmental sources that mimic natural hormones. They can have adverse effects on the morphology, physiology, growth, and development of different organs and systems, among these bone health can be affected too. EDCs work as agonists or antagonists on hormonal receptors in hormone-sensitive cells, influence gene expression by epigenetic mechanisms, stimulate or inhibit cell maturation, and affect the synthesis and metabolism of hormones. This review aims to summarize current evidence on the effects of exposure to EDCs on bone from early gestational to birth and long-term adverse effects. Single and mixtures of endocrine-disrupting chemicals can disrupt bone structure by modifying differentiation, increasing osteoclast activity, inhibiting pre-osteoblasts differentiation into mature osteoblasts and osteocytes, inducing changes in signaling pathways downstream of receptors, and ultimately remodeling and modifying the equilibrium between bone resorption and formation leading to increased bone resorption, morphological, and functional changes in bone maturation. EDCs can affect the IGF system, alkaline phosphatase, and osteocalcin gene expression. Findings are relative to both in vitro and in vivo studies. Studies have shown that prenatal exposure to EDCs leads to growth retardation, delayed ossification, and changes in bone length and size and in bone geometry with a lowering of bone mineral density and area-adjusted bone mineral content. Current knowledge on bone health, growth, mineral content, and development from molecular to clinical findings highlights how endocrine-disrupting chemicals can negatively affect these processes. Mechanisms, however, are not fully understood and need further investigation.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
According to the World Health Organization, approximately 800 chemicals worldwide are known or suspected to be capable of interfering with hormone receptors, hormone synthesis, or hormone metabolism and are defined as endocrine-disrupting chemicals (EDCs) (Bergman 2013). EDCs can have adverse effects on the morphology, physiology, growth, development, reproduction or lifespan of an organism, system, or (sub)population and may act as agonists at one hormone receptor, and as antagonists at another (ECHA, EFSA 2018). EDCs disrupt endocrine functions mainly by mimicking natural hormones like estrogens, androgens, or thyroid hormones (Bergman 2013; ECHA, EFSA 2018; Monneret 2017). They represent a heterogeneous group of natural and man-made chemicals that can be found in different environmental sources: agricultural practices (pesticides, insecticides, and fungicides), packaging (plastics, pesticides, and metals in several everyday products, including plastic bottles and food storage containers), industry (solvents, flame retardants, preservatives, emulsifiers, fracking chemicals), consumer products (household chemicals, cosmetics, flame retardants, building materials, children’s toys, electronic devices and media, cookware, water pipes), medical care (resin-based dental sealants and bonding agents, oral contraceptives, biocides, intravenous bags and tubing, disposable gloves, disinfectants), and even meat, fish, and vegetables (Bergman 2013; ECHA, EFSA 2018; ATSDR 2002; Thent et al. 2018; Vasantha et al. 2021).
Plastics and plasticizers (bisphenol A (BPA) and phthalates), pesticides, parabens, perfluoroalkyl and polyfluoroalkyl substances, dioxins, brominated flame retardants, metal, and metalloids are widespread EDCs. People are exposed to EDCs directly through oral and topical routes and indirectly via environmental pollution and food chain (Bergman 2013; ECHA, EFSA 2018; Chin et al. 2018).
The most sensitive window of EDCs exposure for the subsequent effects is during critical periods of development; fetal development and puberty are recognized as such (Bergman 2013). There are lipophilic and non-lipophilic endocrine disruptive chemicals. Non-lipophilic chemicals are transported bound to albumin and stored in the liver in humans (Alcala et al. 2019). The lipophilic chemical structure of some EDCs allows them to cross the blood–placental and blood–brain barriers that lead to prenatal fetus exposure and can be delivered through lactation to infants (Pohjanvirta and Tuomisto 1994; Ünüvar and Büyükgebiz 2012; Tang et al. 2020; Rolfo et al. 2020; Street and Bernasconi 2020). The biological effects of EDCs are carried out by their binding to various receptors in the body affecting body weight, cardiovascular system, glucose metabolism, reproductive function, neurodevelopment and the neuroendocrine system, including the skeletal system as one of the target organs (Bergman 2013; ECHA, EFSA 2018; Street and Bernasconi 2020). Several studies have shown that the action of EDCs is mediated also through the regulation of epigenetic mechanisms such as histone deacetylase activity, mitogen-activated protein kinase activity, and DNA methylation status influencing gene expression by epigenetic mechanisms (Tang et al. 2020; Jones and Baylin 2002; Anway and Skinner 2006; Huen et al. 2016; Lizunkova et al. 2022).
Finally, exposure to endocrine-disrupting chemicals has been associated with the altered regulation of skeletal formation and of the bone remodeling process (Bonefeld-Jørgensen et al. 2007; Agas et al. 2013, 2018). EDCs can act as bone toxicants with implications for bone mass accrual during adolescence (Hu et al. 2019; Carwile et al. 2022) and may induce either increased bone resorption or inhibition of bone deposition (Chin et al. 2018; Smith et al. 2017; Hwang et al. 2013; Toni et al. 2020).
Since EDCs influence biological processes associated with bone health, they may impact skeletal development and the pathogenesis of osteoporosis later in life. A number of studies have been performed to investigate the action of EDCs in the skeleton and its derivatives, but the results are inconsistent.
This narrative review aims to summarize current evidence on the effects of exposure to EDCs on bone from early gestational, at birth and long-term adverse effects.
Methodology
The MEDLINE PubMed, Mendeley, and Scopus databases were searched to identify the relevant studies. The following keywords «EDCs», «endocrine-disrupting chemicals», «bone», and «growth» were used. The selection criteria for the literature research were text availability (full text), article type (books and documents, clinical trial, meta-analysis, randomized controlled trial, review, mini-review, and systematic review), language (English), species (rodents and humans), and child age (birth-18 years), publication date range (2001–2022).
The literature review was conducted in compliance with the recommendations provided in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Figure 1 shows the PRISMA flowchart with identified studies, those included and excluded.
Overall, from the literature search, 159 articles were included in this review for analysis.
Main Mechanisms of Bone Growth and Mechanisms of Action of EDCs
Bone growth and development are a complicated hormone-dependent process (Yaglova and Yaglov 2021; Salhotra et al. 2020). Bone development begins with the replacement of mesenchymal tissue into bone tissue (Fig. 2). This process of bone formation occurs through two basic mechanisms. The first is intramembranous bone formation, when bone forms inside the mesenchymal membrane (ex., skull and jaw); this forms a woven bone, a bone form with randomly organized collagen fibers that are further remodeled into mature lamellar bone, with regular parallel collagen rings and consists of osteocytes (Yaglova and Yaglov 2021; Salhotra et al. 2020; Setiawati and Rahardjo 2018). The second is endochondral bone formation, where bone replaces hyaline cartilage (precursor to bone formation). Lamellar bone is then constantly remodeled by osteoclasts and osteoblasts. Osteoblasts are cells originating from osteoprogenitor cells, forming osteoid, that allows matrix mineralization. Osteoclasts are hemopoietic lineages cells that break down bone matrix through phagocytosis during bone formation and remodeling (Yaglova and Yaglov 2021; Salhotra et al. 2020; Setiawati and Rahardjo 2018).
Bone growth consists of two processes: interstitial epiphyseal growth and appositional growth. During interstitial epiphyseal growth (bone elongation), the growth plate with the zonal organization of endochondral ossification allows bones to lengthen without epiphyseal growth plates enlarging zones. On the epiphyseal side, cartilage is formed; on the diaphyseal side, cartilage is ossified, and the diaphysis then grows in length. During appositional growth, osteoclasts resorb old bone that lines the medullary cavity, while osteoblasts, via intramembranous ossification, produce new bone tissue (Yaglova and Yaglov 2021; Salhotra et al. 2020; Setiawati and Rahardjo 2018).
Bone remodeling is a key dynamic process that requires osteoclasts, derived from the hematopoietic lineage and responsible for bone resorption, osteoblasts derived from the mesenchymal lineage and responsible for bone formation, and osteocytes derived from terminally differentiated osteoblasts permanently entombed in the bone matrix. (Bergman 2013; Chin et al. 2018; Salhotra et al. 2020; Setiawati and Rahardjo 2018; Florencio-Silva et al. 2015). The bone remodeling process is regulated by several hormones and by local factors, among these: the parathyroid hormone (Yaglova and Yaglov 2021; Florencio-Silva et al. 2015; Hodsman et al. 2003), thyroid hormones (triiodothyronine, thyroxine, calcitonin) (Yaglova and Yaglov 2021), bone morphogenetic proteins (Agas et al. 2018; Salhotra et al. 2020), prostaglandins (Agas et al. 2013, 2018; Toni et al. 2020; Sabbieti et al. 2009, 2008), testosterone, estrogen and progesterone, somatotropin and somatostatin, and adrenal cortex hormones (Yaglova and Yaglov 2021).
Growth hormone (GH) is a hormone produced by the pituitary somatotroph cells and nonpituitary tissues that act directly and indirectly on the epiphyseal plates of long bones and also has a metabolic function. One of the growth hormone predominant actions is hepatic synthesis and secretion of insulin growth factor-1 (IGF-1), and its synthesis by osteoblasts and chondrocytes, suggesting local synthesis contributes also to the regulation of statural growth (LeRoith 2008). The IGF system is important in mammalian cell growth, proliferation, and development and consists of two IGF ligands, insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-2 (IGF-2), two IGF receptors (IGF-1 receptor (IGF-1R) and IGF-2 receptor (IGF-2R)), and six IGF binding proteins (IGFBPs) and several binding protein proteases that regulate IGF bioactivity (Renehan et al. 2006; Bach et al. 2005). GH increases the expression through the signaling pathways of both IGF-1 and IGFBP-3 besides through its own receptor, and by regulating IGFBP-4 and -5 of alkaline phosphatase and type I procollagen mRNA expression favoring bone formation (Blum et al. 2018). IGFBPs modulate IGF-I bioavailability regulating in turn skeletal, homeostasis (Kawai and Rosen 2012). For instance, these proteins may inhibit the actions of IGF-1 by preventing access to the IGF-1R in bone (Kawai and Rosen 2012). In addition, bone formation is regulated through the activation of the IGF-1-GSK-3β-RUNX2-mediated signaling pathway and runt-related transcription factor-2 (RUNX2) regulation and release (Toni et al. 2020). IGF-2 shares biochemical and biological properties with IGF-1 and is important in skeletal development, but its synthesis is not GH-dependent (Giustina et al. 2008).
Several studies showed that microRNAs (miRNA) have an important role in the regulation of the GH/IGF-1 axis and the IGF system, bone homeostasis, and, in particular, osteoclast formation (Scheller et al. 2011; Catellani et al. 2022). Estrogen and xenoestrogens can modulate miRNA expression, some pri-miRNA genes contain estrogen response elements (EREs) in their promoters and can be regulated by the activity of estrogen receptors (ERα and ERβ) (Sabry et al. 2019). Low-dose EDCs can upregulate enzyme aromatase (CYP19) mRNA, increase CYP19 activity, significantly increase CYP19-induced biosynthesis of the breast carcinogen 17β-E2, and increase ERα-positive breast cell proliferation (Williams and Darbre 2019).
Steroids are implicated in bone growth, mineralization, and remodeling. Steroids can suppress autophagy to cause osteoblasts and osteocytes apoptosis, enhance osteoclast activity, and decrease osteoprotegerin synthesis, and they play the main role in bone mineral metabolism for the attainment of peak bone mass during puberty and maintaining bone mass and strength during adulthood (Yaglova and Yaglov 2021; Mitra 2011).
EDCs can bind nuclear receptors (NRs), especially the androgen and estrogen receptors (ERs), the glucocorticoid receptor (GR), the mineralocorticoid receptor, the thyroid hormone receptors, the retinoid X receptor (RXR) and the peroxisome proliferator-activated receptors (PPARs) (Agas et al. 2018; Swedenborg et al. 2009; Alavian-Ghavanini and Rüegg 2018). The nuclear receptors together with glucocorticoid receptors and the aryl hydrocarbon receptor (AhR) regulate DNA methylation at a specific gene locus through interactions with DNA methyltransferases (DNMTs) (Agas et al. 2018; Kouzmenko et al. 2010). The direct or indirect EDC–receptor interactions lead to different epigenetic alterations such as changes in DNA methylation and histone acetylation (Agas et al. 2018; Swedenborg et al. 2009). EDCs may alter DNA methylation patterns in an ER-dependent way (Alavian-Ghavanini and Rüegg 2018; Kitraki et al. 2015) or through interaction with the AhR (Alavian-Ghavanini and Rüegg 2018; Romagnolo et al. 2016). The EDC vinclozolin, a fungicide, and androgen receptor antagonist were shown to induce a marked increase in DNA methyltransferases mRNA expression in vivo through an AR-mediated pathway (Alavian-Ghavanini and Rüegg 2018). The receptor activator of NF-kappaB (RANK) is critical for differentiation and activation of osteoclasts and RUNX2 is important as a key transcription factor for osteoblastogenesis (Hwang et al. 2013; Xin et al. 2018; Shoucri et al. 2017). By reducing the RANK ligand or its receptor availability, EDCs may induce a net loss in RANK/RANKL signaling, ultimately impairing osteoclast activity. Also, EDCs bound ERα capable to stimulate and repress of RUNX2 activity in human and rodent osteoblasts (Xin et al. 2018). Histone post-translational modifications, including methylation and acetylation, are epigenetic marks capable of influencing gene expression through alterations in chromatin accessibility, for bone development and homeostasis, but studies on how EDCs affect histone post-translational modifications are yet limited (Xin et al. 2018; Shoucri et al. 2017). Estrogen deficiency can be caused by inflammation and oxidative stress through increased TNF-α, IL-6, TLR-2, TLR-4, changes in NF-κB, and increased ROS production which all lead to increased bone resorption (Mohamad et al. 2020).
Any disruption of molecular mediators of bone formation and remodeling has an effect on bone strength, architecture, and density parameters such as bone mineral density (BMD) and bone mineral content (BMC), bending force, hardness, plasticity of bones, and so on (Agas et al. 2013, 2018; Carwile et al. 2022; Smith et al. 2017; Lejonklou et al. 2016; Miettinen et al. 2005; Hermsen et al. 2008; Finnilä et al. 2010). As EDCs may affect the modeling and remodeling of bone structure, they can contribute to an achievement of lower bone mass which is the main determinant of early osteoporosis in offspring (Miki et al. 2016).
In Vitro Evidence of Adverse Effects of EDCs on Bone
Several experiments have shown how single EDCs can cause disruption in bone cells causing changes in metabolism, and morphological, and functional changes in bone maturation (Bergman 2013). Xenoestrogens exert an effect by binding α and β estrogen receptors on osteoblasts and osteoclasts. EDCs as xenoestrogens influence bone structure by disrupting differentiation, downstream signaling pathways of receptors, ultimately remodeling, and modifying the equilibrium between bone resorption and formation (Fig. 3) (Agas et al. 2018; Yaglova and Yaglov 2021; Salhotra et al. 2020; Bolli et al. 2008; Ronis et al. 2020; García-Recio et al. 2022; Talia et al. 2021).
Bisphenol A, in particular, can bind to estrogen receptors present in bone and cartilage (Agas et al. 2018; Spelsberg et al. 1999; Richmond et al. 2000). Specifically, in vitro experiments showed that Bisphenol A (BPA) treatment induces apoptosis and inhibits osteoclast maturation (Toni et al. 2020; Miki et al. 2016), but studies are yet limited. BPA is structurally similar to endogenous 17β-oestradiol (E2), and via binding both estrogen receptors (ER) α and β (Bolli et al. 2008) can inhibit the expression of RUNX2 and Osterix (OSX), which activates genes during differentiation of pre-osteoblasts into mature osteoblasts and osteocytes, and the Wnt/b-catenin signaling pathway in the MC3T3-E1 mouse cell line. RUNX2 and OSX are key for differentiation as they reduce the expression of the markers of differentiation alkaline phosphatase (ALP), collagen-1 (COL-1), osteocalcin (OCN), bone morphogenetic protein 2 (BMP-2), and bone morphogenetic protein 7 (BMP-7) with an overall negative effect not only on the maturation of osteoblasts but also on their functional capacity (Toni et al. 2020; García-Recio et al. 2022). Furthermore, García-Recio et al. (2022) described a negative effect of BPA on bone matrix formation; in particular, they described changes in the expression of CD54 and CD80, where reduced expression was associated with osteoblast differentiation and elevated expression with suppression of osteoblasts differentiation (García-Recio et al. 2022). BPA had a negative effect also on alkaline phosphatase activity and bone matrix formation, and on osteoblasts mineralization (García-Recio et al. 2022). These same authors, in a further in vitro study, showed that BPA treatment caused a significant reduction in the expression of COL-1, ALP, OCN, RUNX2, OSX, BMP-2, and BMP-7, modifying human osteoblast differentiation, antigen, and gene expression in primary cultures resulting in an inhibition of growth (García-Recio et al. 2022).
Bisphenol A may impact the IGF system also by promoting the expression of IGF-1R and inducing IGF-1 expression (Talia et al. 2021; Murata and Kang 2018). In addition, bisphenol A can activate the human steroid xenobiotic receptor (SXR) and cause xenobiotic receptor (SXR)-mediated transcription on the SXR response elements by recruiting SRC-1 to the ligand-binding domain of SXR in osteoblast-like MG-63 cells, in fetal bone tissue (Miki et al. 2016; Ichikawa et al. 2006). A further study by Urano et al. (2009) defined a nucleotide polymorphism in the SXR gene that was significantly associated with high bone mineral density in primary osteoblasts (Urano et al. 2009).
Dioxin has been described in an in vitro study to be able to suppress bone deposition by inhibiting osteoblastogenesis through the dependent aryl hydrocarbon receptor (AhR), the extracellular signal`lated kinases activation, and by Wnt/b-catenin signaling suppression (Iqbal et al. 2015) affecting the IGF system also by inhibiting IGF-1, IGF-2, and IGF-1R mRNA expression (Talia et al. 2021; Liu et al. 1992; Croutch et al. 2005a).
Polychlorinated biphenyl (PCB)-126 exposure was associated with decreased serum osteocalcin, no change in bone resorption markers, and with a significant reduction in serum calcium levels associated with an increase in parathyroid hormone, which represents an appropriate response to the calcium reduction. Osteoblastogenesis suppression was hypothesized to be blunted by the AhR antagonist in the presence of PCB-126 (Ronis et al. 2020). PCBs have been shown to be able to disrupt the estrogen-relatedγ39 receptor that negatively regulates BMP-2-induced osteoblast differentiation and bone formation (Hu et al. 2019; Kiess et al. 2021) and can contribute to an increased risk of osteoporosis in the exposed population.
Perfluoroalkyl substances (PFAS) and phthalates can affect bone homeostasis through the activation of peroxisome proliferator-activated receptor gamma (PPARγ) (Yamamoto et al. 2015; Szilagyi et al. 2020), by suppressing osteoblast formation and acting as androgen receptor antagonists possibly inhibiting androgen-mediated osteoblastogenesis (Smith et al. 2017; Kjeldsen and Bonefeld-Jørgensen 2013; Engel et al. 2017) or by directly intercalating into bone (Bogdanska et al. 2014; Koskela et al. 2017; Pérez et al. 2013). In human endometrial stromal cells, PFOS can decrease the IGFBP-1 transcript (Yang et al. 2016).
Di-2-ethylhexyl phthalate (DEHP) treatment (100 µM) has been described to decrease the expression of RUNX2 and of its transcriptional coactivator with PDZ-binding motif (TAZ) at the protein level, leading to a decreased collagen matrix secretion and mineralization, besides decreased ALP mRNA expression suggesting impaired osteoblast differentiation and maturation (Bhat et al. 2013). Benzyl butyl phthalate (BBP) and di-n-butyl phthalate (DBP) are estrogen-mimicking compounds that modify the cytoplasmic fibroblast growth factor-2 (FGF-2) translocation into the nucleus in rat osteoblasts (Menghi et al. 2001). In particular, the exposure to 10–9 to10−6 M of BBP and DBP induces FGF-2 perinuclear accumulation with subsequent translocation into the nucleus (Menghi et al. 2001) that may modify gene transcription (Hu et al. 2019; LeRoith 2008; Menghi et al. 2001; Jiang et al. 2015).
In vitro studies have reported that alkylphenols influence bone architecture through the downregulation of critical factors, such as tartrate-resistant acid phosphatase (TRAP) and macrophage colony-stimulating factor (M-CSF) leading to changes in bone matrix organization, in osteoblast and osteoclast differentiation by inhibiting osteoclast formation and affecting stromal cells and osteoclast-supporting cells (Hagiwara et al. 2008).
Butyltin trichloride is used as a polyvinyl chloride stabilizer, wood preservative, and as biocide for cooling systems. In vitro exposure to tributyltin chloride (TBT) (10–10 to 10–7) suppressed the expression levels of alkaline phosphatase and osteocalcin, markers of bone differentiation, and interfered with calcium signaling and deposition in rat calvarial osteoblast-like (ROB) cells. Thus, the observed delayed ossification of the fetal skeleton could be ascribed to the changes induced by TBT on important differentiating markers and signaling cascades (Tsukamoto et al. 2004).
Finally, EDCs have immunomodulatory effects also and may induce either increased bone resorption or inhibit bone deposition and lead to disruption of skeletal homeostatic preservation (Agas et al. 2018; Hu et al. 2019; Yaglova and Yaglov 2021; Ronis et al. 2020; Yang et al. 2016; Hwang et al. 2017; Ramajayam et al. 2007).
Table 1 summarizes the findings of the effects of EDCs in bone in in vitro studies.
In Vivo Evidence of Adverse Effects of EDCs on Bone (Rodent Models)
Many studies have shown the effects of EDCs on bone development and structure in rodents (Table 2).
Bisphenol A is one of the most common and most studied EDCs as it is transferred across the placenta of rat dams to the fetus (Moors et al. 2006). Chemek and Nevoral (2019) reported that low-dose BPA exposure potentially alters the epigenetic pattern in the testes, including increased IGF-2 gene methylation and decreased protein lysine acetylation (Mao et al. 2015; Chemek and Nevoral 2019). The in vivo murine studies have shown that BPA inhibits osteoblast proliferation and induces apoptosis, ALP synthesis, calcium nodule formation, and the expression of RUNX2, OSX, and β catenin genes, which are markers of bone differentiation (Rolfo et al. 2020; García-Recio et al. 2022; Zhang et al. 2021). Kim et al. (2001) observed delayed ossification of fetal rat skeletons after administration by gavage of the BPA chemical to mated females from days 1 to 20 of gestation at high doses such as 100, 300, and 1,000 mg/kg/day (daily dose volume 10 ml/kg body weight) (Kim et al. 2001). However, other studies showed that lower doses (0.1 and 1% w/w) of this chemical in diet, for 5 months, prevented bone loss in female mice lacking the aromatase gene CYP19 (Toda et al. 2002), and thus lacking estrogens, confirming the pro-estrogenic effect of BPA. In particular, in that study, the BPA diet completely reversed the loss of femoral trabecular bone observed in the CYP19 knockout mice, by increasing femoral bone mineral density in a dose-dependent manner (1% w/w BPA administration was more effective than 0.1% w/w) without altering femoral bone density in wild-type mice (Toda et al. 2002). In rodents, bisphenol A exposure (50 μg/kg BPA/day diluted in 0.1% ethanol for 7 days) during early pregnancy led to growth retardation (Müller et al. 2018). Low-dose bisphenol A exposure (0.5 µg/kg BW/day) in pregnant rats reduced bone length and size in the male rat offspring, determining specifically femoral bone shortening and decreased trabecular area (Lind et al. 2017; Pelch et al. 2012) and higher exposure doses (10–25 mg/kg/day) showed sexual dimorphic changes on bone geometrics and increased femoral length in both male and female offspring (Hu et al. 2019; Lejonklou et al. 2016). The most recent study by Wang et al. (2021) showed that exposure to 10 μg/kg per day of BPA throughout pregnancy delayed bone development and bone mass was reduced in the female rat offspring, and these effects were mediated by the suppression of the osteogenic function via the ERβ/HDAC5/TGFβ signaling pathway (Wang et al. 2021).
Several researchers have reported negative associations between prenatal exposure to dioxin and dioxin metabolites administration and IGF-2 mRNA expression and protein levels (Wu et al. 2004; Ding et al. 2018; Ma et al. 2015; Zhang et al. 2019), but Wang et al. (2011) reported an increase in both mRNA expression and protein (Wang et al. 2021, 2011). Prenatal exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) in mice during the preimplantation stage was related with decreased IGF-2 mRNA expression in a whole-body analysis of embryos (Wu et al. 2004). Interestingly, a transgenerational study reported that both in F1 male mice exposed prenatally to a dioxin single dose (10 μg/kg body weight) on gestational day 15 (GD15) (direct prenatal dioxin exposure) and in F3 male descendants (ancestral exposure), decreased placental IGF-2 content was observed (Ding et al. 2018). Prenatal exposure to TCDD (0.8 μg/kg body weight/day, from gestational day 8 to 14) also decreased both the transcript and protein levels of IGF-2 in adult livers of F1 rats (Ma et al. 2015). This is opposite to the findings of Wang et al. (Wang et al. 2011) (10 μg/kg body weight single TCDD exposure on gestational day 10) who described increased IGF-2 in fetal livers (Wang et al. 2011). Different levels of exposure and timing besides different approaches to analyses may have contributed to these different results. Korkalainen et al. (2009) reported that dioxin exposure diminished bone growth through aryl hydrocarbon receptor (AhR) in rodents (Korkalainen et al. 2009; Turan 2021). In adult rats exposed to dioxin, both chronically and with a single large dose, circulating IGF-1 levels were found to be significantly decreased (Croutch et al. 2005b; Linden et al. 2014). Moreover, dioxin treatment induced hepatic IGFBP-1 mRNA expression (Minami et al. 2008). TCDD treatment in mice induced IGFBP-6 in the thymus and bone marrow, at both the transcriptional and protein levels, with the finding being confirmed in vitro using a thymoma cell line (EL-4) (Park et al. 2001, 2003). Administration of 0.03, 0.1, 0.3, or 1 l g/kg TCDD at different time points in rodents significantly decreased tibia and femur length and cross-sectional areas of the cortex and determined a smaller endosteal and periosteal circumference in both these long bones (Hu et al. 2019; Miettinen et al. 2005).
Few in vivo studies have explored the effects associated with polychlorinated biphenyl administration. Rats prenatally exposed to PCB-126 present reduced circulating levels of both IGF-1 and IGF-2 (Talia et al. 2021; Ahmed et al. 2018). Skeletal toxicity after exposure to PCB-126 is a result of disruption of calcium homeostasis and of the GH-IGF-1 axis and involves once again direct AhR-mediated effects on bone formation and decreases long bone length and diameter with increasing trabecular thickness and volume (Ronis et al. 2020).
Recent studies have reported that exposure to PFOS, administered orally to rodents at 1, 5, or 10 mg/kg by gavage, was associated with the downregulation of IGF-1 mRNA expression levels, key for longitudinal bone growth, and of IGF-1R mRNA expression in the liver and testes (Ohlsson et al. 2009; Wan et al. 2011). Exposure to 0.3 mg·kg−1·day−1 PFOA mixed with food in pregnant rats led to increased femoral periosteal area, with a parallel decrease in the mineral density of tibias in offspring. Researchers reported also that PFOA decreased osteoblast activity secondary to increased vitamin D levels and altered vitamin D-responsive genes (Turan 2021; Nisio et al. 2020), accumulated in bone and consequently exerted persistent deleterious effects on bone geometry and mineral density (Hu et al. 2019; Koskela et al. 2017).
In vivo studies have also reported an increased number of skeletal malformations, such as deformity of the thoracic vertebrae and fusion of the vertebral arches, in rat fetuses exposed to phthalates and phthalate metabolites (Agas et al. 2018; Sabbieti et al. 2008; Ema et al. 1993). More specifically, DBP exposure upregulated mRNA expression for IGF-1, IGF-2, IGF-1R, and IGF binding protein 5 (IGFBP5) genes and for matrix metalloproteinase (Agas et al. 2018; Talia et al. 2021; Bowman et al. 2005). Liu et al. (2018) observed elevated G protein-coupled receptor 54 (GPR54) and gonadotropin-releasing hormone (GnRH) protein expression in the hypothalamus and increased release of Kiss-1 mRNA, allowing for stimulation of GnRH secretion with increased IGF-1 and GH in rats treated with 500 mg/kg/d and 1000 mg/kg/d DEHP (Liu et al. 2018). Negative associations have been consistently reported among DEHP and the percentage of methylated CpG sites in IGF-2R in rodents’ primordial germ cells (Li et al. 2014).
There are few studies on the effects of alkylphenols’ on bones. Hagiwara et al. (2008) reported that exposure to 0.1 mg/kg p-n-nonylphenol (NP) or p-n-octylphenol (OP) treatment accelerated the ossification of the sternum bone in the fetuses, as compared to the control group of rodents. The NP and OP were further confirmed to inhibit the formation of osteoclasts in vitro. But alkylphenols did not affect the proliferation and differentiation of rat calvarial osteoblast-like cells (Hagiwara et al. 2008).
Transplacental tributyltin chloride exposure at the doses of 10 or 20 mg/kg, from 0 to 19 gestation days in rodents, was associated with reduced ossification in the fetuses. The 20 mg/kg concentration caused misaligned sternum or sternoschisis with delayed ossification of the fetal pelvic girdle, skull, and limbs, while doses of 10 mg/kg reduced bone formation of the sternum (Talia et al. 2021; Tsukamoto et al. 2004; Adeeko et al. 2003; Sarpa et al. 2007). Injection of 1 mg of TBT or MBT/kg body weight to pregnant mice was associated with delayed ossification of the supraoccipital bone, metacarpals, and metatarsals (Tsukamoto et al. 2004). In a further study, the rodent TBT-treated group exhibited a decreased osteogenic capacity of the stromal stem cells and increased adipogenic differentiation capacities (Kirchner et al. 2010). High concentrations of TBT resulted in decreased ALP mRNA levels (culture day 6) and decreased OCN, which led to bone homeostasis impairment (Tsukamoto et al. 2004; Koskela et al. 2012). However, the findings by Carvalho Rangel Resgala et al.(2019) were different as these authors reported that TBT treatment (100 ng/kg/day TBT for 15 days) led to higher bone mineral density and observed increased osteocalcin, alkaline phosphatase, and urinary deoxipyridinolines excretion ratios, as markers of bone resorption and on microCT scans or with scanning electron microscopy detected lesions in the spinal bones (Resgala et al. 2019).
Current Evidence of Adverse Effects of EDCs on Growth and Bone in Humans in Childhood
Prenatal and early postnatal periods have been shown to be the most vulnerable periods of life for endocrine disruption since organs and systems are developing and changing more intensively (Huen et al. 2016; Smith et al. 2017; Anway et al. 2005). Prenatal exposure to EDCs may affect the fetus directly or dysregulate placental functions, insulin, glucocorticoid, estrogenic, and thyroid hormonal pathways, epigenetic regulation of gene expression, and inflammatory pathways (Jones and Baylin 2002). There are few epidemiological studies that have focused on the impact of epigenetic changes owing to prenatal exposures to EDCs within the context of growth, metabolic programming, and bone health. Kim et al. (2018) showed that in utero exposure to EDCs can perturb normal biological functions via the epigenome (Kim et al. 2018). In particular, they showed that dichlorodiphenyltrichloroethane (DDTs), including p,p′-DDT, can influence the methylation of two key imprinted genes, i.e., IGF-2/H19, in the placenta, showing a significant association between a 1% increase in placental long interspersed nuclear element-1 (LINE-1) methylation with a 0.19 cm decrease in birth length (β = − 0.19; 95% CI = − 0.35 to − 0.03). However, placental methylation of neither IGF-2 nor H19 was significantly associated with the birth outcome parameters measured (Kim et al. 2018). Although this study showed many limitations as the limited number of subjects in the population study, the heterogeneous nature of cells in the placenta, and potential changes in the exposure to POPs throughout gestation that were not taken into consideration (Kim et al. 2018), the findings are consistent with another study which observed hypomethylation of LINE-1, IGF-2, and PPARA after exposure to increasing phthalate concentrations (Montrose et al. 2018), and with the Goodrich et al. (2016) ELEMENT study where phthalate exposure in the third trimester of pregnancy altered H19 methylation in children. H19 is important for the regulation of body composition and growth (Goodrich et al. 2016). With regard to bisphenol A, exposure during human embryonic body differentiation was confirmed to be associated with downregulation of IGF-1 and IGF-1R mRNA expression with subsequent changes in fetal development (Huang et al. 2017).
Body mass index (BMI) is an another factor that has an effect on bone health as it can affect bones through a variety of mechanisms, including body weight, fat volume, bone formation/resorption, and proinflammatory cytokines together with bone marrow microenvironment (Hou et al. 2020). Extremely low BMI and oppositely obesity have a direct negative influence on bone marrow adipose tissue with subsequent significant clinical effects on bone density and strength. Additional visceral fat may contribute to bone loss. Possibly because both osteoblasts and fat cells are derived from the mesenchymal stem cells in the bone marrow, an increase in adipogenic differentiation could potentially result in a reduction of osteogenic differentiation of these mesenchymal stem cells (Hou et al. 2020). Different studies showed that prenatal exposure to EDCs is associated with increased BMI in childhood which can indirectly affect bone health (Harley et al. 2017).
Figure 4 summarizes the adverse effects exercised by single EDC during fetal life on mechanisms involved with future bone health.
Bisphenol
High maternal bisphenol S urine concentrations have been directly associated with a larger head circumference and higher birth weight and lower risk of being small for gestational age at birth, especially when exposure occurs mainly during the first trimester of pregnancy (Sol et al.2021). Similar findings were reported in a further study that described an association between high bisphenol A concentrations in children’s urine and increased BMI z-score at 4 years of age, whereas prenatal exposure (high BPA concentrations in mother’s urine) was negatively associated with BMI and measures of adiposity in girls and positively in boys, but with no other growth parameters (Vafeiadi et al. 2015). Recent Snijder et al. and Ish et al. studies, which used a job exposure matrix to identify EDCs, reported no relationships between bisphenols and fetal or infant growth (Snijder et al. 2012; Ish et al. 2022).
Specifically for bone, a 10-year population-based prospective cohort study reported that maternal serum bisphenol S levels in the first trimester of gestation were associated with lower childhood bone mineral density (BMD) and area-adjusted bone mineral content (aBMC) in 10-year-old children. However, there were no associations between maternal serum total and specific bisphenol concentrations and bone measures at 6 years of age, and no associations between BPA and bone measurements at both 6 and 10 years (Zwol-Janssens et al. 2020).
Dioxins and Organochlorine Pesticides
Exposure to dioxins and dioxin-like compounds is known to be associated with increased IGF-1 circulating levels in children and decreased IGF-1 serum concentrations in adults (Talia et al. 2021). Placental weight and birth weight are positively associated with IGF-1 and IGFBP-3 levels at birth and later in childhood (Talia et al. 2021). Interestingly, studies of prenatal exposure to high levels of polychlorinated biphenyls showed low IGFBP-3 levels in 8-year-old girls and high IGF-1 levels in 5-year-old boys (Su et al. 2010, 2015). These results were partially confirmed in further longitudinal cohort study, in which pre- and early postnatal exposure to dioxin-like compounds were associated with increased IGF-1 levels in 3-month-old infants, accelerated longitudinal growth, and weight gain (Wohlfahrt-Veje et al. 2014). But in the more recent CHECK cohort study by Kim et al. (2018), no significant association was observed between p,p′‑dichloro‑diphenyl dichloroethylene (p,p′DDE) or PCB levels and placental LINE-1, a retrotransposon and marker of methylation (Kim et al. 2018), and a further significant positive association was described with placental IGF-2 methylation levels.
Elevated prenatal exposure to Σ19-organochlorine pesticides (Σ19OCPs) was associated significantly with increased IGF-2 methylation and decreased H19 methylation in the placenta. The CHECK cohort that consisted of 109 placental samples and maternal blood during delivery found a positive association between exposure to Σ6DDTs and birth length and a suggestive inverse association between Σ6DDTs and LINE-1 methylation (β = − 0.63; 95% CI = − 1.36 to 0.11) in the placenta. This study did not show an association between placental DNA methylation and birth weight but defined a significant relationship with reduced birth length (p < 0.05) (Kim et al. 2018).
Iszatt et al. (2015) described an increase in infant growth associated with prenatal p,p′-DDE and a decrease associated with postnatal polychlorinated biphenyl 153 (PCB-153) exposure (Iszatt et al. 2015). A similar relationship was described by Cock et al. also, between low exposure to p,p´-DDE and growth during the first year of life (Iszatt et al. 2015). For PCB-153 exposure, changes in length were significant during the first 3 months of postnatal life in both sexes, but not thereafter (Cock et al. 2014).
In the prospective study by Vafeiadi et al. (RHEA, 2015), consisting of a cohort of 689 mother–child pairs, where prenatal and neonatal serum samples were obtained and a 4-year observation period was carried out for children, hexachlorobenzene (HCB) concentrations were found to be positively but not significantly associated with rapid growth during the first 6 months of life (Vafeiadi et al. 2015). HCB exposure was associated with a higher BMI z-score that showed no significant association with HCB, p,p′-DDE, and PCBs exposure at the end of follow-up (Vafeiadi et al. 2015). A further study confirmed the association of HCB exposure with BMI z-score in preschool children (Karlsen et al. 2017). Previous studies, however, found no associations between PCB or p,p′-DDE exposures and length and growth in infants independent of maternal race and child sex (Pan et al. 2010).
Height was significantly different depending on PCDD/Fs exposure levels at 2 (p = 0.0029) and 5 years of age (p = 0.0276) in boys and girls (Su et al. 2010). Considering the male and female subgroups, height, weight, chronological age, and bone age were significantly different depending on the exposure levels to PCDD/Fs at 2 years in females, whereas no differences were reported in males. Children who were exposed to PCDD/Fs had higher levels of T3, and IGF-1 at 2 years of age being significantly higher in females than in males. Furthermore, at age 5 yr, the most exposed had higher serum IGF-I, prevailing in the males with respect to females (Ish et al. 2022). A further study did not detect any effect of exposure to dioxin on children’s anthropometric measurements (Delvaux et al. 2014).
Phthalates and Their Metabolites
Since in vivo studies have shown that exposure to phthalates has an effect on longitudinal bone growth and bone remodeling, we examined the studies related with prenatal and postnatal exposure to phthalates. Boas et al. (2010) described a negative correlation with both IGF-1 and IGFBP-3 serum concentrations (Boas et al. 2010). Tsai et al. (2016) described a negative association of measurements of exposure to DEHP exposure with IGF-1, height and weight, but no association with IGFBP-3 (Tsai et al. 2016) whereas a negative association among some phthalate metabolites (MEP and MMP) and IGF-1 and IGFBP-3 levels was confirmed further by a recent study by (Huang et al. 2020).
One study proved that when a phthalate metabolite mixture was considered, the effect of exposure during pregnancy on abdominal circumference and femur length was greater than single phthalate exposure. All phthalate metabolites were modestly and inversely associated with birth size in single-pollutant analyses. It was also shown that a one-quartile increase in exposure in the pregnancy-averaged phthalate metabolite mixture was inversely associated with birth length (p = 0.14). At birth, male infants were 0.5 cm shorter for each one-quartile increase compared to girls (Stevens et al. 2022). This is in agreement with the findings by Botton et al. (2016) where MBzP levels during the third trimester of pregnancy contributed the most to the effects of the phthalate metabolite mixture on birth length (Botton et al. 2016). Snijder et al. (2012) also found that fetal length was negatively associated with phthalate and pesticide exposure (Snijder et al. 2012) whereas a very recent study found no associations with growth (Ish et al. 2022).
Several studies have evaluated the associations of exposure to phthalate metabolites with BMI. Cock et al. described that low exposure was associated with higher BMI values, and high exposure levels were associated with greater head circumference (Cock et al. 2014). DEHP exposure, especially MECPP and MEHHP, possibly affected the growth parameters during the first year of life (Cock et al. 2014).
A study that included outcomes over a 20-year period found a negative association between changes in height z-score at 2 years of age, and maternal phthalate metabolite concentrations for MHBP and MCiOP in maternal serum samples at 18 and 34 weeks of gestation. Before 2 years of age, participants who had detectable serum MHBP or MCiOP levels grew, respectively, on average of 0.73 cm and 0.66 cm less compared to those children who had undetectable levels. Between 2 and 10 years of age, significant positive relationships were detected between height z-score and higher exposure to MBzP and MECPP. Participants with detectable levels of MBzP were 1.19 cm taller than participants with undetectable levels of MBzP. Participants in the middle and upper tertiles of exposure to MECPP were 0.99 cm taller than those in the lowest tertile, respectively. Weak positive associations between some of the phthalate metabolites and height z-score were detected during childhood. However, up to 20 years of age, associations between maternal phthalates and dual-energy X-ray absorptiometry outcomes were not defined (Berman et al. 2021).
Maternal exposure to MCNP and MCPP measured in urine has been associated with increased fetal femoral length in the second and third trimesters and with increased length at birth. After birth, MBzP exposure was positively associated with height in the two first years of life; however, after 5 years of follow-up, maternal urinary concentrations of MEP were positively associated with weight growth velocity from 2 years onwards, with weight at 3 and 5 years and BMI at 5 years of age (Botton et al. 2016). Interestingly, the most recent study by Ish et al. (2022) did not find evidence of associations between any exposure to EDCs and femur length (Ish et al. 2022). The ten-year follow-up study by van Zwol-Janssens et al. (2020) described no association between exposure to phthalates and BMD and adjusted BMC both in 6- and 10-year-old children (Zwol-Janssens et al. 2020).
Perfluoroalkyl Substances (PFAS)
Exposure to PFAS has also been associated with lower levels of IGF-1 and sex hormones in 2292 children aged 6–9 years (Lopez-Espinosa et al. 2016).
Maisonet et al. (2012) found that girls born to mothers with higher serum PFAS concentrations during pregnancy were smaller at birth and heavier at 20 months with respect to controls. And the PFHxS metabolite had a statistically significant association with reduced birth length (Maisonet et al. 2012). Consistently, a statistically significant association between maternal PFHxS and a decreased birth length was found by Lee et al. (2013). Although the authors described that this effect disappeared after adjustment for gestational age in the crude model, it became significant again after adjusting for both gestational and maternal age (Lee et al. 2013). A lower birth length was found also in the HOME (2021) study (Buckley et al. 2021), but not in the study by Cock et al. (Wohlfahrt-Veje et al. 2014). In a two-year follow-up study, Shoaff et al.(2018) did not detect any significant associations between child growth and PFAS exposure, except for the association between PFHxS and rapid growth (Shoaff et al. 2018). Birth length and head circumference seemed to have no relationships with PFAAs exposure either and no associations were found between maternal PFAA levels and childhood growth during the first 5 years of life (Gyllenhammar et al. 2018). Louis et al. (2018), however, described in Hispanic women, a negative association between PBDE #28 levels in mothers’ serum and child length. In black mothers, serum PFOA, PFOSA, and PBDE #153 levels were negatively associated with child length, and in White women, a positive association between PFOA, PFOSA, and child length was further detected. In this study, PFDA was the only EDC associated with upper arm length, and some PFASs, specifically N-MeFOSA, PFDA, PFHpA, PFHxS, PFNA, PFOA, and PFUnDA, were found to be associated with reductions (cm) in upper thigh length. These findings apparently were most predominant among caucasic versus other ethnic neonates (Buck Louis et al. 2018).
The NHANES study reported that PFAS serum levels and urinary phthalate biomarkers may be associated with reduced bone mineral density in 12–19-year-old adolescents. In this study, by using Bayesian kernel machine regression, the authors estimated that higher concentrations of PFOA, PFOS, MBP, and MiBP were related with lower aBMD Z-scores in boys, whereas in girls higher concentrations of PFOA and MiBP were related with higher aBMD Z-scores (Smith et al. 2017). Similarly, Project Viva showed that higher PFAS plasma concentrations were associated with lower aBMD z-scores in covariate-adjusted models, with the strongest associations holding for PFOA, PFOS, and PFDA. The strongest significant association was found between PFAS exposure and aBMD z-score in girls (Cluett et al. 2019).
The HOME study associated maternal serum PFOA, PFNA, and PFAS mixture concentrations with lower BMC z-scores in children in particular at the hip and forearm. The associations of PFOA in maternal serum concentrations with bone outcome z-scores were generally stronger among males than females (Buckley et al. 2021). Similar results were observed in the ODENSE (2022) study, where children with higher prenatal PFAS exposure and with higher PFAS serum concentrations at 18 months of age had lower BMC and BMD Z-scores at 7 years of age. All associations between PFAS and BMC were significant, whereas only PFNA and PFDA were significantly associated with reduced BMD. Furthermore, adjustment for child sex, height Z-score at age 7 years, and maternal education analyses showed that the effect of 18 months of exposure appeared to affect more bone mineral content than bone mineral density (Højsager et al. 2022). Perfluorononanoic acid also had an association with reduced bone mineral density in the Khalil et al. (2018) study in school-age children, but this association was statistically insignificant after adjusting for multiple testing (Khalil et al. 2018).
The ALSPAC study followed up girls for 17 years established that prenatal PFOS, PFOA, PFHxS, and PFNA concentrations in maternal serum collected during pregnancy were negatively correlated with bone size and mass in a confounder-adjusted analysis for age, gestational age, and maternal education. Interestingly, hip BMD had no significant association with prenatal PFAS exposure. Conversely, PFNA was positively associated with area-adjusted bone mineral content (Jeddy et al. 2018).
Polycyclic Aromatic Hydrocarbons (PAHs)
Although the lack of epidemiological studies does not give the possibility to describe PAHs impact on the IGF system, a recent study reported a negative association between exposure to PAHs and IGF-1 plasma levels and height (Zeng et al. 2020).
Mothers occupationally exposed to PAHs and phthalates showed significantly lower fetal weight growth rates (average decline in SD per gestational week: 0.01660 for PAHs and 0.01691 for phthalates) compared with non-exposed mothers (Snijder et al. 2012). PAHs have been reported to be associated negatively with children’s birth length; children with higher exposure were shorter compared to lower exposed children (Jedrychowski et al. 2004). At variance with these findings, Perera et al. found associations between PAHs, birth weight (β = –0.08, p = 0.02), and head circumference (β = –0.02, p = 0.04) in African-Americans and no associations with other growth measurements (Perera et al. 2003).
Table 3 and table 4 summarize the effects of endocrine-disrupting chemical exposure on children’s growth and bone health. Table 3 reports the known effects of mixtures and Table 4 reports the effects of single chemicals.
Conclusions and Further Perspectives
Endocrine-disrupting chemicals are commonly found in our environment. Studies suggest that they have an effect on growth and on bone growth, homeostasis, and remodeling, and thus can negatively affect bone health. This prompts the necessity for further knowledge and awareness.
This review provides an overview of the current knowledge on how prenatal endocrine-disrupting chemicals exposure can affect bone growth, length, structure, mineral content, and development. Many in vitro and in vivo studies have shown how single EDCs can negatively affect these processes but the mechanisms are not fully understood. Furthermore, human data are yet scarce but there are many studies that do suggest that prenatal exposure affects longitudinal growth, BMI, and mineral content, thus suggesting that this will have consequences into adult life.
Results have been sometimes inconsistent across studies possibly due to differences in sample size, study design, study populations, life stage, sex, ethnicity, data collecting, data analysis approaches, and/or strategies for attaining data on exposure.
Many of the potential exposure–response relationships described here have not been entirely understood and need further investigation on how EDCs affect bone tissue.
Further studies on the effects of endocrine-disrupting chemicals in children would be relevant and needed to determine their influence on linear growth and skeletal disorders to preserve bone health and prevent diseases and complications in adulthood such as osteoporosis. Longitudinal studies starting from pregnancy would be of particular relevance to study the effects of exposure throughout life. Future research studies will need to understand how different levels of exposure to EDCs can influence bone development before and after birth, considering that the effect of mixtures on BMD is still controversial and poorly understood although more adherent to real life. Another required field of investigation is endocrine disruptor-driven epigenetic changes and their effect on bone remodeling processes and pathways required for growth plate growth, as well as risk factor for patients having growth hormone deficiency, being this latter of key importance for longitudinal bone growth and bone quality. There is a need for preventing exposure to EDCs during pregnancy and early life and for further understanding of the underlying molecular mechanisms to develop possible prevention and therapeutic strategies.
Data Availability
Not applicable.
Abbreviations
- ALP:
-
Alkaline phosphatase
- AhR:
-
Aryl hydrocarbon receptor
- BA:
-
Bone area
- BBP:
-
Phthalate ester benzyl butyl phthalate
- BMC:
-
Bone mineral content
- BMD:
-
Bone mineral density
- BMP:
-
Bone morphogenetic protein
- DBP:
-
Di-n-butyl phthalate
- DXA:
-
Dual-energy X-ray absorptiometry scans
- EDCs:
-
Endocrine-disrupting chemicals
- Ers:
-
Estrogen receptors
- FGF-2:
-
Fibroblast growth factor-2
- HCB:
-
Hexachlorobenzene
- IGF:
-
Insulin-like growth factor
- IGF-1:
-
Insulin growth factor-1
- IGF-1R:
-
Insulin growth factor-1 receptor
- IGF-2:
-
Insulin-like growth factor-2
- IGF-2R:
-
Insulin growth factor-2 receptor
- IGFBP:
-
Insulin-like growth factor binding protein
- LBM:
-
Lean body mass
- M-CSF:
-
Macrophage colony-stimulating factor
- MBP:
-
Monobutyl phthalate
- MBzP:
-
Monobenzyl phthalate
- MCNP:
-
Mono-carboxy-isononyl phthalate
- MCOP:
-
Mono-carboxy-isooctyl phthalate
- MCPP:
-
Mono-3-carboxypropyl phthalate
- MECPP:
-
Mono-2-ethyl-5-carboxypentyl phthalate
- MEHHP:
-
Mono-2-ethyl- 5-hydroxyhexyl phthalate
- MEHP:
-
Mono-2-ethylhexyl phthalate
- MEOHP:
-
Mono-2-ethyl-5-oxohexyl phthalate
- MEP:
-
Monoethyl phthalate
- MiBP:
-
Mono-isobutyl phthalate
- MnBp:
-
Mono-n-butyl phthalate
- NP:
-
P-n-Nonylphenol
- OCN:
-
Osteocalcin
- OCPs:
-
Organochlorine pesticides
- OP:
-
P-n-octylphenol
- OSX:
-
Osterix
- PAHs:
-
Polycyclic aromatic hydrocarbons
- PBDEs:
-
Polybrominated diphenyl ethers
- PCB:
-
Polychlorinated biphenyl
- PCBs/PBBs:
-
Polychlorinated/polybrominated biphenyls
- PCDDs:
-
Polychlorinated dibenzo-p-dioxins
- PCDFs:
-
Polychlorinated dibenzofurans
- PFAS/PFASs:
-
Perfluoroalkyl substances/poly-and-per-fluorinated alkyl substances
- PPARs:
-
Peroxisome proliferator-activated receptors
- PPARγ:
-
Peroxisome proliferator-activated receptor gamma
- RUNX2:
-
Runt-related transcription factor-2
- SXR:
-
Steroid xenobiotic receptor
- TBT:
-
Tributyltin chloride
- TRAP:
-
Tartrate-resistant acid phosphatase
- Wnt:
-
Wnt/b-catenin signaling pathway
- aBMD:
-
Areal bone mineral density
- microRNA:
-
miRNA
- o,P′-DDD:
-
o,p′-dichlorodiphenyldichloroethane
- p,P′- DDE:
-
p,p′-dichlorodiphenyldichloroethylene
- p,P′-DDD:
-
p,p′-dichlorodiphenyldichloroethane
- p,P′-DDT:
-
p,p′-dichlorodiphenyltrichloroethane
- ΣDEHP:
-
Σ Di-2-ethylhexyl phthalate
- β-HCH:
-
Beta-hexachlorocyclohexane
- γ-HCH:
-
Gamma-hexachlorocyclohexane
References
Adeeko A, Li D, Forsyth DS, Casey V, Cooke GM, Barthelemy J et al (2003) Effects of in utero tributyltin chloride exposure in the rat on pregnancy outcome. Toxicol Sci 74:407–415
Agas D, Sabbieti MG, Marchetti L (2013) Endocrine disruptors and bone metabolism. Arch Toxicol 87(4):735–751. https://doi.org/10.1007/s00204-012-0988-y
Agas D, Lacava G, Sabbieti MG (2018) Bone and bone marrow disruption by endocrine-active substances. J Cel Physiol 234(1):192–213. https://doi.org/10.1002/jcp.26837
Ahmed RG, El-Gareib AW, Shaker HM (2018) Gestational 3,3′,4,4′,5-pentachlorobiphenyl (PCB 126) exposure disrupts fetoplacental unit: fetal thyroid-cytokines dysfunction. Life Sci 192:213–220. https://doi.org/10.1016/j.lfs.2017.11.033
Alavian-Ghavanini A, Rüegg J (2018) Understanding epigenetic effects of endocrine disrupting chemicals: from mechanisms to novel test methods. Basic Clin Pharmacol Toxicol 12:38–45. https://doi.org/10.1111/bcpt.12878
Alcala CS, Basilio C, Whitea I, Marchittia SA, Hines EP, Berlin CM, Fenton SE (2019) Environmental chemicals in breast milk. Encycl Environ Health. https://doi.org/10.1016/B978-0-12-409548-9.02139-4
Anway MD, Skinner MK (2006) Epigenetic transgenerational actions of endocrine disruptors. Endocrinology 147:43–49. https://doi.org/10.1210/en.2005-1058
Anway MD et al (2005) Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 308(5727):1466–1469
ATSDR (2002) Toxicological Profile for Di(2-ethylhexyl)phthalate (DEHP). ATSDR (Agency for Toxic Substances and Disease Registry): Atlanta, GA.
Bach LA, Headey SJ, Norton RS (2005) IGF-binding proteins–the pieces are falling into place. Trends Endocrinol Metab 16:228–234. https://doi.org/10.1016/j.tem.2005.05.005
Bergman A (2013) United Nations Environment Programme., & World Health Organization. State of the science of endocrine disrupting chemicals - 2012 an assessment of the state of the science of endocrine disruptors. WHO.
Berman YE, Doherty DA, Main KM et al (2021) Associations between prenatal exposure to phthalates and timing of menarche and growth and adiposity into adulthood: a 20-years birth cohort study. Int J Environ Res Public Health 18(9):4725. https://doi.org/10.3390/ijerph18094725
Bhat FA, Ramajayam G, Parameswari S, Vignesh RC, Karthikeyan S, Senthilkumar K, Karthikeyan GD, Balasubramanian K, Arunakaran J, Srinivasan N (2013) Di 2-ethyl hexyl phthalate affects differentiation and matrix mineralization of rat calvarial osteoblasts in vitro. Toxicol Vitro 27:250–256. https://doi.org/10.1016/j.tiv.2012.09.003
Blum WF, Alherbish A, Alsagheir A, El Awwa A, Kaplan W, Koledova E, Savage MO (2018) The growth hormone-insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocr Connect 7(6):R212–R222. https://doi.org/10.1530/EC-18-0099
Boas M, Frederiksen H, Feldt-Rasmussen U, Skakkebæk NE, Hegedüs L, Hilsted L, Juul A, Main KM (2010) Childhood exposure to phthalates: associations with thyroid function, insulin-like growth factor I, and growth. Environ Health Perspect 118:1458–1464. https://doi.org/10.1289/ehp.0901331
Bogdanska J, Sundström M, Bergström U et al (2014) Tissue distribution of 35S-labelled perfluorobutanesulfonic acid in adult mice following dietary exposure for 1–5 days. Chemosphere 98:28–36. https://doi.org/10.1016/j.chemosphere.2013.09.062
Bolli A, Galluzzo P, Ascenzi P, Del Pozzo G, Manco I, Vietri MT, Mita L, Altucci L, Mita DG, Marino M (2008) Laccase treatment impairs bisphenol A-induced cancer cell proliferation affecting estrogen receptor alpha-dependent rapid signals. IUBMB Life 60(12):843–852. https://doi.org/10.1002/iub.130
Bonefeld-Jørgensen EC, Long M, Hofmeister MV, Vinggaard AM (2007) Endocrine-disrupting potential of bisphenol A, bisphenol A dimethacrylate, 4-n-nonylphenol, and 4-n-octylphenol in vitro: new data and a brief review. Environ Health Perspect 115(1):69–76
Botton J, Philippat C, Calafat AM et al (2016) Phthalate pregnancy exposure and male offspring growth from the intra-uterine period to 5 years of age. Environ Res 151:601–609. https://doi.org/10.1016/j.envres.2016.08.033
Bowman CJ, Turner KJ, Sar M, Barlow NJ, Gaido KW, Foster PMD (2005) Altered gene expression during rat Wolffian duct development following Di(n-Butyl) phthalate exposure. Toxicol Sci 86:161–174
Buck Louis GM, Zhai S, Smarr MM, Grewal J, Zhang C, Grantz KL, Hinkle SN, Sundaram R, Lee S, Honda M, Oh JK, Kannan K (2018) Endocrine disruptors and neonatal anthropometry, NICHD fetal growth studies—singletons. Environ Int 119:515–526. https://doi.org/10.1016/j.envint.2018.07.024
Buckley JP, Kuiper JR, Lanphear BP et al (2021) Associations of maternal serum perfluoroalkyl substances concentrations with early adolescent bone mineral content and density: the health outcomes and measures of the environment (HOME) study. Environ Health Perspect 129(9):97011. https://doi.org/10.1289/EHP9424
Carwile JL, Seshasayee SM, Ahrens KA, Hauser R, Driban JB, Rosen CJ, Gordon CM, Fleisch AF (2022) Serum PFAS and urinary phthalate biomarker concentrations and bone mineral density in 12–19 year olds: 2011–2016 NHANES. J Clin Endocrinol Metab 107:e3343–e3352. https://doi.org/10.1210/clinem/dgac228
Catellani C, Ravegnini G, Sartori C, Righi B, Lazzeroni P, Bonvicini L, Poluzzi S, Cirillo F, Predieri B, Iughetti L, Giorgi Rossi P, Angelini S, Street ME (2022) Specific miRNAs change after 3 months of GH treatment and contribute to explain the growth response after 12 months. Front Endocrinol 13:896640. https://doi.org/10.3389/fendo.2022.896640
Chemek M, Nevoral J (2019) The dark side of the breastfeeding: in the light of endocrine disruptors. Med J Cell Biol 7(1):32–38. https://doi.org/10.2478/acb-2019-0005
Chin KY, Pang KL, Mark-Lee WF (2018) A review on the effects of bisphenol a and its derivatives on skeletal health. In International Journal of Medical Sciences 15(10):1043–1050. https://doi.org/10.7150/ijms.25634.
Cluett R, Seshasayee SM, Rokoff LB et al (2019) Per- and Polyfluoroalkyl substance plasma concentrations and bone mineral density in midchildhood: a cross-sectional study (Project Viva, United States). Environ Health Perspect 127(8):87006. https://doi.org/10.1289/EHP4918
Croutch CR, Lebofsky M, Schramm KW, Terranova PF, Rozman KK (2005a) 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin (HxCDD) alter body weight by decreasing insulin-like growth factor I (IGF-I) signaling. Toxicol Sci 85(1):560–571. https://doi.org/10.1093/toxsci/kfi106
Croutch CR, Lebofsky M, Schramm KW, Terranova PF, Rozman KK (2005b) 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and 1,2,3,4,7,8-hexachlorodibenzo-p- dioxin (HxCDD) alter body weight by decreasing insulin-like growth factor I (IGF-I) signaling. Toxicol Sci 85(1):560–571. https://doi.org/10.1093/toxsci/kfi106
de Cock M, de Boer MR, Lamoree M, Legler J, van de Bor M (2014) First year growth in relation to prenatal exposure to endocrine disruptors—a dutch prospective cohort study. Int J Environ Res Public Health 11(7):7001–7021. https://doi.org/10.3390/ijerph110707001
Delvaux I, Van Cauwenberghe J, Den Hond E et al (2014) Prenatal exposure to environmental contaminants and body composition at age 7–9 years. Environ Res 132:24–32. https://doi.org/10.1016/j.envres.2014.03.019
Di Nisio A, Rocca MS, De Toni L et al (2020) Endocrine disruption of vitamin D activity by perfluoro-octanoic acid (PFOA). Sci Rep 10(1):16789. https://doi.org/10.1038/s41598-020-74026-8
Ding T, Mokshagundam S, Rinaudo PF, Osteen KG, Bruner-Tran KL (2018) Paternal developmental toxicant exposure is associated with epigenetic modulation of sperm and placental Pgr and Igf2 in a mouse model. Biol Reprod 99:864–876. https://doi.org/10.1093/biolre/ioy111
ECHA/EFSA 2018 (2018) Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009. EFSA J 16(6):5311
Ema M, Itami T, Kawasaki H (1993) Teratogenic phase specificity of butyl benzyl phthalate in rats. Toxicology 79:11–19
Engel A, Buhrke T, Imber F et al (2017) Agonistic and antagonistic effects of phthalates and their urinary metabolites on the steroid hormone receptors ERα, ERβ, and AR. Toxicol Lett 277:54–63. https://doi.org/10.1016/j.toxlet.2017.05.028
Finnilä MA, Zioupos P, Herlin M, Miettinen HM, Simanainen U, Håkansson H, Tuukkanen J, Viluksela M, Jämsä T (2010) Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure on bone material properties. J Biomech 43(6):1097–1103. https://doi.org/10.1016/j.jbiomech.2009.12.011
Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simões MJ, Cerri PS (2015) Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int 2015:421746. https://doi.org/10.1155/2015/421746
García-Recio E, Costela-Ruiz VJ, Melguizo-Rodriguez L, Ramos-Torrecillas J, García-Martínez O, Ruiz C, de Luna-Bertos E (2022) Repercussions of bisphenol A on the physiology of human osteoblasts. Int J Mol Sci. https://doi.org/10.3390/ijms23105349
Giustina A, Mazziotti G, Canalis E (2008) Growth Hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29(5):535–559. https://doi.org/10.1210/er.2007-0036
Goodrich JM, Dolinoy DC, Sanchez BN et al (2016) Adolescent epigenetic profiles and environmental exposures from early life through peri-adolescence. Environ Epigenetics 2(3):dvw018
Gyllenhammar I, Diderholm B, Gustafsson J et al (2018) Perfluoroalkyl acid levels in first-time mothers in relation to offspring weight gain and growth. Environ Int 111:191–199. https://doi.org/10.1016/j.envint.2017.12.002
Hagiwara H, Sugizaki T, Tsukamoto Y, Senoh E, Goto T, Ishihara Y (2008) Effects of alkylphenols on bone metabolism in vivo and in vitro. Toxicol Lett 181:13–18
Harley KG, Berger K, Rauch S et al (2017) Association of prenatal urinary phthalate metabolite concentrations and childhood BMI and obesity. Pediatr Res 82(3):405–415. https://doi.org/10.1038/pr.2017.112
Hermsen SA, Larsson S, Arima A, Muneoka A, Ihara T, Sumida H, Fukusato T, Kubota S, Yasuda M, Lind PM (2008) In utero and lactational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) affects bone tissue in rhesus monkeys. Toxicology 253:147–152. https://doi.org/10.1016/j.tox.2008.09.005
Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R (2003) Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212–5220. https://doi.org/10.1210/jc.2003-030768
Højsager FD, Andersen M, Juul A, Nielsen F, Möller S, Christensen HT, Grøntved A, Grandjean P, Jensen TK (2022) Prenatal and early postnatal exposure to perfluoroalkyl substances and bone mineral content and density in the Odense child cohort. Environ Int 167:107417. https://doi.org/10.1016/j.envint.2022.107417
Hou J, He C, He W, Yang M, Luo X, Li C (2020) Obesity and bone health: a complex link. Front Cell Dev Biol 8:600181. https://doi.org/10.3389/fcell.2020.600181
Hu Y, Liu G, Rood J, Liang L, Bray GA, de Jonge L, Coull B, Furtado JD, Qi L, Grandjean P, Sun Q (2019) Perfluoroalkyl substances and changes in bone mineral density: a prospective analysis in the POUNDS-LOST study. Environ Res 179:108775. https://doi.org/10.1016/j.envres.2019.108775
Huang B, Ning S, Zhang Q et al (2017) Bisphenol A represses dopaminergic neuron differentiation from human embryonic stem cells through downregulating the expression of insulin-like growth factor 1. Mol Neurobiol 54(5):3798–3812. https://doi.org/10.1007/s12035-016-9898-y
Huang PC, Chang WH, Wu MT et al (2020) Characterization of phthalate exposure in relation to serum thyroid and growth hormones, and estimated daily intake levels in children exposed to phthalate-tainted products: a longitudinal cohort study. Environ Pollut 264:114648. https://doi.org/10.1016/j.envpol.2020.114648
Huen K, Calafat AM, Bradman A, Yousefi P, Eskenazi B, Holland N (2016) Maternal phthalate exposure during pregnancy is associated with DNA methylation of LINE-1 and Alu repetitive elements in Mexican-American children. Environ Res 148:55–62. https://doi.org/10.1016/j.envres.2016.03.025
Hwang JK, Min KH, Choi KH, Hwang YC, Jeong I-K, Ahn KJ, Chung H-Y, Chang JS (2013) Bisphenol A reduces differentiation and stimulates apoptosis of osteoclasts and osteoblasts. Life Sci 93:367–372. https://doi.org/10.1016/j.lfs.2013.07.020
Hwang YH, Son YJ, Paik MJ, Yee ST (2017) Effects of diisononyl phthalate on osteopenia in intact mice. Toxicol Appl Pharmacol 334:120–128. https://doi.org/10.1016/j.taap.2017.08.016
Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S (2006) Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix- related genes and collagen accumulation in osteoblastic cells. J Biol Chem 281(25):16927–16934. https://doi.org/10.1074/jbc.M600896200
Iqbal K, Tran DA, Li AX, Warden C, Bai AY, Singh P, Wu X, Pfeifer GP, Szabó PE (2015) Deleterious effects of endocrine disruptors are corrected in the mammalian germline by epigenome reprogramming. Genome Biol 16(1):59. https://doi.org/10.1186/s13059-015-0619-z
Ish J, Ruiz G, de Porras D, Symanski E, Ballester F, Casas M et al (2022) Maternal occupational exposures and fetal growth in a Spanish birth cohort. PloS one 17(4):e0264530. https://doi.org/10.1371/journal.pone.0264530
Iszatt N, Stigum H, Verner M-A, White RA, Govarts E, Murinova LP et al (2015) Prenatal and postnatal exposure to persistent organic pollutants and infant growth: a pooled analysis of seven European birth cohorts. Environ Health Perspect 123(7):730–736. https://doi.org/10.1289/ehp.1308005
Jeddy Z, Tobias JH, Taylor EV, Northstone K, Flanders WD, Hartman TJ (2018) Prenatal concentrations of perfluoroalkyl substances and bone health in British girls at age 17. Arch Osteoporos 13(1):84. https://doi.org/10.1007/s11657-018-0498-5
Jedrychowski W, Bendkowska I, Flak E, Penar A, Jacek R, Kaim I, Spengler JD, Camann D, Perera FP (2004) Estimated risk for altered fetal growth resulting from exposure to fine particles during pregnancy: An epidemiologic prospective cohort study in Poland. Environ Health Perspect 112(14):1398–1402. https://doi.org/10.1289/ehp.7065
Jiang JT, Xu HL, Zhu YP et al (2015) Reduced Fgf10/Fgfr2 and androgen receptor (AR) in anorectal malformations male rats induced by di-n-butyl phthalate (DBP): a study on the local and systemic toxicology of DBP. Toxicology 338:77–85. https://doi.org/10.1016/j.tox.2015.10.006
Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428. https://doi.org/10.1038/nrg816
Karlsen M, Grandjean P, Weihe P, Steuerwald U, Oulhote Y, Valvi D (2017) Early-life exposures to persistent organic pollutants in relation to overweight in preschool children. Reprod Toxicol 68:145–153. https://doi.org/10.1016/j.reprotox.2016.08.002
Kawai M, Rosen CJ (2012) The insulin-like growth factor system in bone: basic and clinical implications. Endocrinol Metab Clin North Am 41(2):323–vi. https://doi.org/10.1016/j.ecl.2012.04.013
Khalil N, Ebert JR, Honda M, Lee M, Nahhas RW, Koskela A, Hangartner T, Kannan K (2018) Perfluoroalkyl substances, bone density, and cardio-metabolic risk factors in obese 8–12 year old children: a pilot study. Environ Res 160:314–321. https://doi.org/10.1016/j.envres.2017.10.014
Kiess W, Häussler G, Vogel M (2021) Endocrine-disrupting chemicals and child health. Best Pract Res Clin Endocrinol Metab 35:101516. https://doi.org/10.1016/j.beem.2021.101516
Kim JC, Shin HC, Cha SW, Koh WS, Chung MK, Han SS (2001) Evaluation of developmental toxicity in rats exposed to the environmental estrogen bisphenol A during pregnancy. Life Sci 69:2611–2625
Kim S, Cho YH, Lee I et al (2018) Prenatal exposure to persistent organic pollutants and methylation of LINE-1 and imprinted genes in placenta: a CHECK cohort study. Environ Int 119:398–406. https://doi.org/10.1016/j.envint.2018.06.039
Kirchner S, Kieu T, Chow C, Casey S, Blumberg B (2010) Prenatal exposure to the environmental obesogen tributyltin predisposes multipotent stem cells to become adipocytes. Mol Endocrinol 24:526–539
Kitraki E, Nalvarte I, Alavian-Ghavanini A, Rüegg J (2015) Developmental exposure to bisphenol A alters expression and DNA methylation of Fkbp5, an important regulator of the stress response. Mol Cell Endocrinol 417:191–199. https://doi.org/10.1016/j.mce.2015.09.028
Kjeldsen LS, Bonefeld-Jørgensen EC (2013) Perfluorinated compounds affect the function of sex hormone receptors. Environ Sci Pollut Res Int 20(11):8031–8044. https://doi.org/10.1007/s11356-013-1753-3
Korkalainen M, Kallio E, Olkku A et al (2009) Dioxins interfere with differentiation of osteoblasts and osteoclasts. Bone 44(6):1134–1142. https://doi.org/10.1016/j.bone.2009.02.019
Koskela A, Viluksela M, Keinänen M, Tuukkanen J, Korkalainen M (2012) Synergistic effects of tributyltin and 2,3,7,8-tetrachlorodibenzo-p-dioxin on differentiating osteoblasts and osteoclasts. Toxicol Appl Pharmacol 263(2):210–217. https://doi.org/10.1016/j.taap.2012.06.011
Koskela A, Koponen J, Lehenkari P et al (2017) Perfluoroalkyl substances in human bone: concentrations in bones and effects on bone cell differentiation. Sci Rep 7:6841. https://doi.org/10.1038/s41598-017-07359-6
Kouzmenko A, Ohtake F, Fujiki R, Kato S (2010) Hormonal gene regulation through DNA methylation and demethylation. Epigenomics 2(6):765–774. https://doi.org/10.2217/epi.10.58
Lee YJ, Kim MK, Bae J, Yang JH (2013) Concentrations of perfluoroalkyl compounds in maternal and umbilical cord sera and birth outcomes in Korea. Chemosphere 90(5):1603–1609. https://doi.org/10.1016/j.chemosphere.2012.08.035
Lejonklou MH, Christiansen S, Örberg J, Shen L, Larsson S, Boberg J, Hass U, Lind PM (2016) Low-dose developmental exposure to bisphenol A alters the femoral bone geometry in wistar rats. Chemosphere 164:339–346. https://doi.org/10.1016/j.chemosphere.2016.08.114
LeRoith D (2008) Clinical relevance of systemic and local IGF-I: lessons from animal models. Pediatr Endocrinol Rev 5(2):739
Li L, Zhang T, Qin XS et al (2014) (2014) Exposure to diethylhexyl phthalate (DEHP) results in a heritable modification of imprint genes DNA methylation in mouse oocytes. Mol Biol Rep 41(3):1227–1235. https://doi.org/10.1007/s11033-013-2967-7
Lind T, Lejonklou MH, Dunder L et al (2017) Low-dose developmental exposure to bisphenol A induces sex-specific effects in bone of Fischer 344 rat offspring. Environ Res 159:61–68. https://doi.org/10.1016/j.envres.2017.07.020
Linden J, Lensu S, Pohjanvirta R (2014) Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on hormones of energy balance in a TCDD-sensitive and a TCDD-resistant rat strain. Int J Mol Sci 15:13938–13966. https://doi.org/10.3390/ijms150813938
Liu H, Biegel L, Narasimhan TR, Rowlands C, Safe S (1992) Inhibition of insulin-like growth factor-I responses in MCF-7 cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Mol Cell Endocrinol 87:19–28. https://doi.org/10.1016/0303-7207(92)90229-Y
Liu T, Wang Y, Yang M et al (2018) Di-(2-ethylhexyl) phthalate induces precocious puberty in adolescent female rats. Iran J Basic Med Sci 21(8):848–855. https://doi.org/10.22038/IJBMS.2018.28489.6905
Lizunkova P, Engdahl E, Borbély G, Gennings C, Lindh C, Bornehag C-G, Rüegg J (2022) A Mixture of endocrine disrupting chemicals associated with lower birth weight in children induces adipogenesis and DNA methylation changes in human mesenchymal stem cells. Int J Mol Sci 23(4):2320. https://doi.org/10.3390/ijms23042320
Lopez-Espinosa MJ, Mondal D, Armstrong BG, Eskenazi B, Fletcher T (2016) Perfluoroalkyl Substances, sex hormones, and insulin-like growth factor-1 at 6–9 years of age: a cross-sectional analysis within the C8 health project. Environ Health Perspect 124(8):1269–1275. https://doi.org/10.1289/ehp.1509869
Ma J, Chen X, Liu Y et al (2015) Ancestral TCDD exposure promotes epigenetic transgenerational inheritance of imprinted gene Igf2: Methylation status and DNMTs. Toxicol Appl Pharmacol 289(2):193–202. https://doi.org/10.1016/j.taap.2015.09.024
Maisonet M, Terrell ML, McGeehin MA et al (2012) Maternal concentrations of polyfluoroalkyl compounds during pregnancy and fetal and postnatal growth in British girls. Environ Health Perspect 120(10):1432–1437. https://doi.org/10.1289/ehp.1003096
Mao Z, Xia W, Chang H, Huo W, Li Y, Xu S (2015) Paternal BPA exposure in early life alters Igf2 epigenetic status in sperm and induces pancreatic impairment in rat offspring. Toxicol Lett 238(3):30–38. https://doi.org/10.1016/j.toxlet.2015.08.009
Menghi G, Sabbieti MG, Marchetti L, Menghi M, Materazzi S, Hurley MM (2001) Phthalate esters influence FGF-2 translocation in Py1a rat osteoblasts. Eur J Morphol 39:155–162. https://doi.org/10.1076/ejom.39.3.155.4672
Miettinen HM, Pulkkinen P, Jämsä T, Koistinen J, Simanainen U, Tuomisto J, Tuukkanen J, Viluksela M (2005) Effects of in utero and lactational TCDD exposure on bone development in differentially sensitive rat lines. Toxicol Sci 85:1003–1012. https://doi.org/10.1093/toxsci/kfi136
Miki Y, Hata S, Nagasaki S, Suzuki T, Ito K, Kumamoto H, Sasano H (2016) Steroid and xenobiotic receptor-mediated effects of bisphenol A on human osteoblasts. Life Sci 155:29–35. https://doi.org/10.1016/j.lfs.2016.05.013
Minami K, Nakajima M, Fujiki Y, Katoh M, Gonzalez FJ, Yokoi T (2008) Regulation of insulin-like growth factor binding protein-1 and lipoprotein lipase by the aryl hydrocarbon receptor. J Toxicol Sci 33:405–413. https://doi.org/10.2131/jts.33.405
Mitra R (2011) Adverse effects of corticosteroids on bone metabolism: a review. PM R 3(5):466–471. https://doi.org/10.1016/j.pmrj.2011.02.017
Mohamad NV, Ima-Nirwana S, Chin KY (2020) Are oxidative stress and inflammation mediators of bone loss due to estrogen deficiency? a review of current evidence. Endocr Metab Immune Disord Drug Targets 20(9):1478–1487. https://doi.org/10.2174/1871530320666200604160614
Monneret C (2017) What is an endocrine disruptor? CR Biol 340:403–405
Montrose L, Padmanabhan V, Goodrich JM, Domino SE, Treadwell MC, Meeker JD, Watkins DJ, Dolinoy DC (2018) Maternal levels of endocrine disrupting chemicals in the first trimester of pregnancy are associated with infant cord blood DNA methylation. Epigenetics 13(3):301–309. https://doi.org/10.1080/15592294.2018.1448680
Moors S, Diel P, Degen GH (2006) Toxicokinetics of bisphenol A in pregnant DA/Han rats after single i.v. application. Arch Toxicol 80:647–655
Müller JE, Meyer N, Santamaria CG et al (2018) Bisphenol A exposure during early pregnancy impairs uterine spiral artery remodeling and provokes intrauterine growth restriction in mice. Sci Rep 8(1):9196. https://doi.org/10.1038/s41598-018-27575-y
Murata M, Kang J-H (2018) Bisphenol A (BPA) and cell signaling pathways. Biotechnol Adv 36:311–327. https://doi.org/10.1016/j.biotechadv.2017.12.002
Ohlsson C, Mohan S, Sjögren K et al (2009) The role of liver-derived insulin-like growth factor-I. Endocr Rev 30(5):494–535. https://doi.org/10.1210/er.2009-0010
Pan IJ, Daniels JL, Herring AH, Rogan WJ, Siega-Riz AM, Goldman BD, Sjödin A (2010) Lactational exposure to polychlorinated biphenyls, dichlorodiphenyltrichloroethane, and dichlorodiphenyldichloroethylene and infant growth: an analysis of the Pregnancy, Infection, and Nutrition Babies Study. Paediatr Perinat Epidemiol 24(3):262–271. https://doi.org/10.1111/j.1365-3016.2010.01114.x
Park JH, Lee S-W, Kim I-T, Shin B-S, Cheong S-W, Cho U-H, Huh M-J, Oh G-S (2001) TCDD-up-regulation of IGFBP-6 and IL-5R alpha subunit genes in vivo and in vitro. Mol Cells 12:372–379
Park JH, Hahn EJ, Kong JH, Cho HJ, Yoon CS, Cheong SW, Oh GS, Youn HJ (2003) TCDD-induced apoptosis in EL-4 cells deficient of the aryl hydrocarbon receptor and down-regulation of IGFBP-6 prevented the apoptotic cell death. Toxicol Lett 145:55–68. https://doi.org/10.1016/S0378-4274(03)00259-5
Pelch KE, Carleton SM, Phillips CL, Nagel SC (2012) Developmental exposure to xenoestrogens at low doses alters femur length and tensile strength in adult mice. Biol Reprod 86(3):69. https://doi.org/10.1095/biolreprod.111.096545
Perera FP, Rauh V, Tsai WY, Kinney P, Camann D, Barr D, Bernert T, Garfinkel R, Tu YH, Diaz D, Dietrich J, Whyatt RM (2003) Effects of transplacental exposure to environmental pollutants on birth outcomes in a multiethnic population. Environ Health Perspect 111(2):201–205. https://doi.org/10.1289/ehp.5742
Pérez F, Nadal M, Navarro-Ortega A et al (2013) Accumulation of perfluoroalkyl substances in human tissues. Environ Int 59:354–362
Pohjanvirta R, Tuomisto J (1994) Short-term toxicity of 2,3,7, 8-tetrachlorodibenzo-p-dioxin in laboratory animals: Effects, mechanisms and animal models. Pharmacol Rev 46:483–549
Ramajayam G, Sridhar M, Karthikeyan S et al (2007) Effects of Aroclor 1254 on femoral bone metabolism in adult male Wistar rats. Toxicology 241(3):99–105. https://doi.org/10.1016/j.tox.2007.08.086
Renehan AG, Frystyk J, Flyvbjerg A (2006) Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17:328–336. https://doi.org/10.1016/j.tem.2006.08.006
Resgala LCR, Santana HS, Portela BSM et al (2019) Effects of tributyltin (TBT) on rat bone and mineral metabolism. Cell Physiol Biochem 52(5):1166–1177. https://doi.org/10.33594/000000079
Richmond RR, Register TC, Shanker G, Loeser RF (2000) Functional estrogen receptors in adult articular cartilage. Arthritis Rheum 43:2081–2090
Rolfo A, Nuzzo AM, de Amicis R, Moretti L, Bertoli S, Leone A (2020) Fetal–maternal exposure to endocrine disruptors: correlation with diet intake and pregnancy outcomes. Nutrients 12(6):1744. https://doi.org/10.3390/nu12061744
Romagnolo DF, Daniels KD, Grunwald JT, Ramos SA, Propper CR, Selmin OI (2016) Epigenetics of breast cancer: Modifying role of environmental and bioactive food compounds. Mol Nutr Food Res 60(6):1310–1329. https://doi.org/10.1002/mnfr.201501063
Ronis MJ, Watt J, Pulliam CF, Williams AE, Alund AW, Haque E, Gadupudi GS, Robertson LW (2020) Skeletal toxicity resulting from exposure of growing male rats to coplanar PCB 126 is associated with disruption of calcium homeostasis and the GH-IGF-1 axis and direct effects on bone formation. Arch Toxicol 94(2):389–399. https://doi.org/10.1007/s00204-019-02645-w
Sabbieti MG, Agas D, Materazzi S, Capacchietti M, Materazzi G, Hurley MM, Menghi G, Marchetti M (2008) Prostaglandin F2a involves heparan sulfate sugar chains and FGFRs to modulate osteoblast growth and differentiation. J Cell Physiol 217:48–59. https://doi.org/10.1002/jcp.21471
Sabbieti MG, Agas D, Santoni G, Materazzi S, Menghi G, Marchetti L (2009) Involvement of p53 in phthalate effects on mouse and rat osteoblasts. J Cell Biochem 107:316–327. https://doi.org/10.1002/jcb.22127
Sabry R, Yamate J, Favetta L, LaMarre J (2019) MicroRNAs: potential targets and agents of endocrine disruption in female reproduction. J Toxicol Pathol 32(4):213–221. https://doi.org/10.1293/tox.2019-0054
Salhotra A, Shah HN, Levi B, Longaker MT (2020) Mechanisms of bone development and repair. Nat Rev Mol Cell Biol 21(11):696–711. https://doi.org/10.1038/s41580-020-00279-w
Sarpa M, De-Carvalho RR, Delgado IF, Paumgartten FJ (2007) Developmental toxicity of triphenyltin hydroxide in mice. Regul Toxicol Pharmacol 49(1):43–52. https://doi.org/10.1016/j.yrtph.2007.05.006
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S (2011) The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813:878–88. https://doi.org/10.1016/j.bbamcr.2011.01.034
Setiawati R, Rahardjo P (2018) Bone Development and Growth. In: Yang, H., editor. Osteogenesis and Bone Regeneration [Internet]. London: IntechOpen; [cited 2022 Nov 20]. Available from: https://www.intechopen.com/chapters/64747 doi:https://doi.org/10.5772/intechopen.82452.
Shoaff J, Papandonatos GD, Calafat AM et al (2018) Prenatal exposure to perfluoroalkyl substances: infant birth weight and early life growth. Environ Epidemiol 2(2):e010. https://doi.org/10.1097/EE9.0000000000000010
Shoucri BM, Martinez ES, Abreo TJ, Hung VT, Moosova Z, Shioda T, Blumberg B (2017) Retinoid X receptor activation alters the chromatin landscape to commit mesenchymal stem cells to the adipose lineage. Endocrinology 158(10):3109–3125. https://doi.org/10.1210/en.2017-00348
Smith JT, Schneider AD, Katchko KM, Yun C, Hsu EL (2017) Environmental factors impacting bone-relevant chemokines. Front Endocrinol 8:22. https://doi.org/10.3389/fendo.2017.00022
Snijder CA, Roeleveld N, Te Velde E et al (2012) Occupational exposure to chemicals and fetal growth: the generation R study. Hum Reprod 27(3):910–920. https://doi.org/10.1093/humrep/der437
Sol CM, van Zwol-Janssens C, Philips EM, Asimakopoulos AG, Martinez-Moral MP, Kannan K, Jaddoe VWV, Trasande L, Santos S (2021) Maternal bisphenol urine concentrations, fetal growth and adverse birth outcomes: a population-based prospective cohort. Environ Health: A Glob Access Sci Sour. https://doi.org/10.1186/s12940-021-00747-6
Spelsberg TC, Subramaniam M, Riggs BL, Khosla S (1999) The actions and interactions of sex steroids and growth factors/ cytokines on the skeleton. Mol Endocrinol 3:819–828. https://doi.org/10.1210/mend.13.6.0299
Stevens DR, Bommarito PA, Keil AP et al (2022) Urinary phthalate metabolite mixtures in pregnancy and fetal growth: findings from the infant development and the environment study. Environ Int 163:107235. https://doi.org/10.1016/j.envint.2022.107235
Street ME, Bernasconi S (2020) Endocrine-disrupting chemicals in human fetal growth. Int J Mol Sci 21(4):1430. https://doi.org/10.3390/ijms21041430
Su PH, Chen JY, Chen JW, Wang SL (2010) Growth and thyroid function in children with in utero exposure to dioxin: a 5-year follow-up study. Pediatr Res 67(2):205–210. https://doi.org/10.1203/PDR.0b013e3181c8f04b
Su PH, Chen HY, Chen SJ, Chen JY, Liou SH, Wang SL (2015) Thyroid and growth hormone concentrations in 8-year-old children exposed in utero to dioxins and polychlorinated biphenyls. J Toxicol Sci 40(3):309–319. https://doi.org/10.2131/jts.40.309
Swedenborg E, Ruegg J, Makela S, Pongratz I (2009) Endocrine disruptive chemicals: mechanisms of action and involvement in metabolic disorders. J Mol Endocrinol 43:1–10. https://doi.org/10.1677/JME-08-0132
Szilagyi JT, Avula V, Fry RC (2020) Perfluoroalkyl substances (PFAS) and their effects on the placenta, pregnancy, and child development: a potential mechanistic role for placental peroxisome proliferator-activated receptors (PPARs). Curr Environ Health Rep 7(3):222–230. https://doi.org/10.1007/s40572-020-00279-0
Talia C, Connolly L, Fowler PA (2021) The insulin-like growth factor system: a target for endocrine disruptors? Environ Int. https://doi.org/10.1016/j.envint.2020.106311
Tang ZR, Xu XL, Deng SL, Lian ZX, Yu K (2020) Oestrogenic endocrine disruptors in the placenta and the fetus. Int J Mol Sci 21(4):1519. https://doi.org/10.3390/ijms21041519
Thent ZC, Froemming GRA, Muid S (2018) Bisphenol A exposure disturbs the bone metabolism: an evolving interest towards an old culprit. Life Sci 198:1–7. https://doi.org/10.1016/j.lfs.2018.02.013
Toda K, Miyaura C, OkadaShizuta T (2002) Dietary bisphenol A prevents ovarian degeneration and bone loss in female mice lacking the aromatase gene (Cyp19). Eur J Biochem 269(8):2214–2222. https://doi.org/10.1046/j.1432-1033.2002.02879.x
Toni R, di Conza G, Barbaro F, Zini N, Consolini E, Dallatana D, Antoniel M, Quarantini E, Quarantini M, Maioli S, Bruni CA, Elviri L, Panseri S, Sprio S, Sandri M, Tampieri A (2020) Microtopography of immune cells in osteoporosis and bone lesions by endocrine disruptors. Front Immunol 11:1–9. https://doi.org/10.3389/fimmu.2020.01737
Tsai Y-A, Lin C-L, Hou J-H, Huang P-C, Lee M-C, Chen B-H, Wu MT et al (2016) Effects of high di(2-ethylhexyl) phthalate (DEHP) exposure due to tainted food intake on pre-pubertal growth characteristics in a Taiwanese population. Environ Res 149:197–205. https://doi.org/10.1016/j.envres.2016.05.005
Tsukamoto Y, Ishihara Y, Miyagawa-Tomita S, Hagiwara H (2004) Inhibition of ossification in vivo and differentiation of osteoblasts in vitro by tributyltin. Biochem Pharmacol 68(4):739–746. https://doi.org/10.1016/j.bcp.2004.04.020
Turan S (2021) Endocrine disrupting chemicals and bone. Best Pract Res Clin Endocrinol Metab 35(5):101495. https://doi.org/10.1016/j.beem.2021.101495
Ünüvar T, Büyükgebiz A (2012) Fetal and neonatal endocrine disruptors. JCRPE J Clin Res Pediatr Endocrinol 4(2):51–60. https://doi.org/10.4274/Jcrpe.569
Urano T, Usui T, Shiraki M, Ouchi Y, Inoue S (2009) Association of a single nucleotide polymorphism in the constitutive androstane receptor gene with bone mineral density. Geriatr Gerontol Int 9(3):235–241. https://doi.org/10.1111/j.1447-0594.2009.00527.x
Vafeiadi M, Georgiou V, Chalkiadaki G et al (2015) Association of prenatal exposure to persistent organic pollutants with obesity and cardiometabolic traits in early childhood: the rhea mother-child cohort (Crete, Greece). Environ Health Perspect 123(10):1015–1021. https://doi.org/10.1289/ehp.1409062
van Zwol-Janssens C, Trasande L, Asimakopoulos AG et al (2020) Fetal exposure to bisphenols and phthalates and childhood bone mass: a population-based prospective cohort study. Environ Res 186:109602. https://doi.org/10.1016/j.envres.2020.109602
Vasantha P, Wenhui S, Muraly P, Praegnatio P (2021) Impact of endocrine-disrupting chemicals. Endocr Rev 42(3):295–353. https://doi.org/10.1210/endrev/bnaa035
Wan HT, Zhao YG, Wong MH, Lee KF, Yeung WSB, Giesy JP, Wong CKC (2011) Testicular signaling is the potential target of perfluorooctanesulfonate- mediated subfertility in male mice1. Biol Reprod 84:1016–1023
Wang J, Liu X, Li T, Liu C, Zhao Y (2011) Increased hepatic Igf2 gene expression involves C/EBPβ in TCDD-induced teratogenesis in rats. Reprod Toxicol 32(3):313–321. https://doi.org/10.1016/j.reprotox.2011.06.117
Wang T, Xu F, Song L, Li J, Wang Q (2021) Bisphenol A exposure prenatally delays bone development and bone mass accumulation in female rat offspring via the ERbeta/HDAC5/TGFbeta signaling pathway. Toxicology 458:152830
Williams GP, Darbre PD (2019) Low-dose environmental endocrine disruptors, increase aromatase activity, estradiol biosynthesis and cell proliferation in human breast cells. Mol Cell Endocrinol 486:55–64. https://doi.org/10.1016/j.mce.2019.02.016
Wohlfahrt-Veje C, Audouze K, Brunak S, Antignac JP, Le Bizec B, Juul A, Skakkebæk NE, Main KM (2014) Polychlorinated dibenzo-p-dioxins, furans, and biphenyls (PCDDs/PCDFs and PCBs) in breast milk and early childhood growth and IGF1. Reproduction 147:391–399. https://doi.org/10.1530/REP-13-0422
Wu Q, Ohsako S, Ishimura R, Suzuki JS, Tohyama C (2004) Exposure of mouse preimplantation embryos to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) Alters the methylation status of imprinted genes H19 and Igf2. Biol Reprod 70(6):1790–1797. https://doi.org/10.1095/biolreprod.103.025387
Xin F, Smith LM, Susiarjo M, Bartolomei MS, Jepsen KJ (2018) Endocrine-disrupting chemicals, epigenetics, and skeletal system dysfunction: exploration of links using bisphenol A as a model system. Environ Epigenetics 4(2):dvy002. https://doi.org/10.1093/eep/dvy002
Yaglova NV, Yaglov VV (2021) Endocrine disruptors as a new etiologic factor of bone tissue diseases (Review). Sovrem Tehnol v Med 13(2):84–96. https://doi.org/10.17691/stm2021.13.2.10
Yamamoto J, Yamane T, Oishi Y, Kobayashi-Hattori K (2015) Perfluorooctanoic acid binds to peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation in 3T3-L1 adipocytes. Biosci Biotechnol Biochem 79(4):636–9
Yang Q, Wang W, Liu C, Wang Y, Sun K (2016) Effect of PFOS on glucocorticoid-induced changes in human decidual stromal cells in the first trimester of pregnancy. Reprod Toxicol 63:142–150. https://doi.org/10.1016/j.reprotox.2016.06.003
Zeng Z, Huo X, Wang Q, Wang C, Hylkema MN, Xu X (2020) PM2.5-bound PAHs exposure linked with low plasma insulin-like growth factor 1 levels and reduced child height. Environ Int 138:105660. https://doi.org/10.1016/j.envint.2020.105660
Zhang X, Ji M, Tan X, Yu K, Xu L, Chen G, Yu Z (2019) Role of epigenetic regulation of Igf2 and H19 in 2,3,7,8-Tetrachlorobenzo-p-dioxin (TCDD)-induced ovarian toxicity in offspring rats. Toxicol Lett 311:98–104. https://doi.org/10.1016/j.toxlet.2019.04.034
Zhang Y, Yan M, Kuang S, Lou Y, Wu S, Li Y, Wang Z, Mao H (2021) Bisphenol A induces apoptosis and autophagy in murine osteocytes MLO-Y4: Involvement of ROS-mediated mTOR/ULK1 pathway. Ecotoxicol Environ Saf 230:113119. https://doi.org/10.1016/j.ecoenv.2021.113119
Acknowledgements
Not applicable.
Funding
Open access funding provided by Università degli Studi di Parma within the CRUI-CARE Agreement. This research received no external funding.
Author information
Authors and Affiliations
Contributions
All authors gave final approval of the final version and are accountable for this work. MES and A-MS contributed to conceptualization; A-MS and MES contributed to methodology; A-MS contributed to resources; A-MS and MES contributed to writing—original draft preparation; MES, A-MS, and PP contributed to writing—review and editing; A-MS contributed to visualization; MES contributed to table editing; and MES and PP contributed to supervision. All authors gave final approval of the final version and are accountable for this work.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Ethical Approval and Consent to Participate
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Shulhai, AM., Palanza, P. & Street, M.E. Current Evidence on the Effects of Endocrine-Disrupting Chemicals (EDCs) on Bone Growth and Health. Expo Health 16, 1001–1025 (2024). https://doi.org/10.1007/s12403-023-00607-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12403-023-00607-3